201653--3/31/2006--DIALYSIS_CORP_OF

related topics

{regulation, government, change}

{acquisition, growth, future}

{competitive, industry, competition}

{personnel, key, retain}

{loss, insurance, financial}

{stock, price, operating}

{stock, price, share}

{product, liability, claim}

{control, financial, internal}

Until fiscal 2001, we had experienced operational losses Dialysis operations are subject to extensive government regulation Our arrangements with our physician medical directors do not meet the safe harbor provisions of federal and state laws, and may subject us to greater governmental scrutiny Our operations are subject to Medicare and Medicaid audits with concurrent potential civil and criminal penalties for failure to comply There has been increased governmental focus and enforcement with respect to anti-fraud initiatives as they relate to healthcare providers Our revenues and financial stability are dependent on fixed reimbursement rates under Medicare and Medicaid Decreases in reimbursement payments from third-party, non-government payors could adversely affect our earnings Any decrease in the availability of or the reimbursement rate of EPO would reduce our revenues and earnings The implementation of the case-mix adjustment could adversely affect our revenues, profitability and cash flow. New Amgen drug could affect use of EPO, adversely impacting our profitability. Our ability to grow is subject to our resources and available locations Our attempt to expand through development or acquisition of dialysis centers which are not currently identified entails risks which shareholders and investors will not have a basis to evaluate We depend on physician referrals, and the limitation or cessation of such referrals would adversely impact our revenues and earnings Industry changes could adversely affect our business Our business is subject to substantial competition, and we must compete effectively, otherwise our growth could slow We could be subject to professional liability claims that may adversely affect us Our insurance costs and deductibles have been substantially increasing over the last several years, and may not be sufficient to cover claims and losses The loss of certain executive personnel without retaining qualified replacements could adversely affect our business operations, and as a result, our revenues and earnings could decline Shares eligible for future sale by restricted shareholders may adversely affect our stock price Over the last year, our stock price has exhibited volatility, and any investment in our common stock may, therefore, decline for reasons unrelated to our performance

Full 10-K form ▸

201653--3/31/2006--DIALYSIS_CORP_OF_AMERICA